Market Cap 44.96M
Revenue (ttm) 0.00
Net Income (ttm) -83.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.08
Volume 2,936
Avg Vol 36,930
Day's Range N/A - N/A
Shares Out 7.32M
Stochastic %K 35%
Beta 0.55
Analysts Hold
Price Target $6.00

Company Profile

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261,...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 822 5600
Address:
4000 Shoreline Court, Suite 300, South San Francisco, United States
BEATOFtheMARKET
BEATOFtheMARKET Jan. 13 at 11:10 PM
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Jan. 12 at 4:14 PM
$LQDA $BARK $EOLS $KZR Cycle Trading Signal 🔥 app 🔥
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Jan. 11 at 10:45 PM
$LQDA $BARK $EOLS $KZR Cycle Trading Signal 🔥 app 🔥 built-in Momentum trigger buy and pullback signal
0 · Reply
JohnTrack
JohnTrack Jan. 9 at 11:24 AM
$KZR Regulatory Update https://www.rapidticker.com/news/kzr-kezar-life-sciences-announces-regulatory-96deb2
0 · Reply
DARKP00L
DARKP00L Jan. 9 at 11:11 AM
$KZR 06:04 on Jan. 09 2026 Kezar Life Sciences Granted FDA Type C Meeting In Q1 To Discuss Zetomipzomib Development And Potential Global Randomized Phase 2b Study In Relapsed And Refractory Autoimmune Hepatitis #tradeideas
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 30 at 1:01 AM
$KZR Share Price: $6.34 Contract Selected: Jul 17, 2026 $10 Calls Buy Zone: $0.31 – $0.38 Target Zone: $0.56 – $0.68 Potential Upside: 72% ROI Time to Expiration: 199 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 24 at 4:57 PM
$KZR NEED TO SHUFFLE 14.7 MILLION SHARES ON U OFF THE BOOKS
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 22 at 9:28 PM
0 · Reply
Adrianople117
Adrianople117 Nov. 17 at 5:49 AM
$KZR Well there goes 500k shares... cant sell 500k at once otherwise it would collapse the stock. Wait for more fomr 13s to come out this week.
0 · Reply
d_risk
d_risk Nov. 12 at 10:28 PM
$KZR - Kezar Life Sciences, Inc. - 10Q - Updated Risk Factors KZR’s latest 10-Q risk factors expand on capital needs, clinical trial and regulatory hurdles, strategic alternatives, restructuring uncertainties, IP and patent challenges, executive retention, cybersecurity, global volatility, concentrated ownership, and new compliance and anti-takeover risks. #Biotechnology #Cybersecurity #CapitalNeeds #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/KZR/10-Q/2025-11-12
0 · Reply
Latest News on KZR
Kezar Life Sciences Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 4:01 PM EST - 2 months ago

Kezar Life Sciences Reports Third Quarter 2025 Financial Results


Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

Oct 28, 2024, 8:30 AM EDT - 1 year ago

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split


Kezar Life Sciences halts mid-stage trial for lupus treatment

Sep 30, 2024, 8:46 AM EDT - 1 year ago

Kezar Life Sciences halts mid-stage trial for lupus treatment


Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023

Mar 6, 2023, 7:00 AM EST - 3 years ago

Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023


BEATOFtheMARKET
BEATOFtheMARKET Jan. 13 at 11:10 PM
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Jan. 12 at 4:14 PM
$LQDA $BARK $EOLS $KZR Cycle Trading Signal 🔥 app 🔥
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Jan. 11 at 10:45 PM
$LQDA $BARK $EOLS $KZR Cycle Trading Signal 🔥 app 🔥 built-in Momentum trigger buy and pullback signal
0 · Reply
JohnTrack
JohnTrack Jan. 9 at 11:24 AM
$KZR Regulatory Update https://www.rapidticker.com/news/kzr-kezar-life-sciences-announces-regulatory-96deb2
0 · Reply
DARKP00L
DARKP00L Jan. 9 at 11:11 AM
$KZR 06:04 on Jan. 09 2026 Kezar Life Sciences Granted FDA Type C Meeting In Q1 To Discuss Zetomipzomib Development And Potential Global Randomized Phase 2b Study In Relapsed And Refractory Autoimmune Hepatitis #tradeideas
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 30 at 1:01 AM
$KZR Share Price: $6.34 Contract Selected: Jul 17, 2026 $10 Calls Buy Zone: $0.31 – $0.38 Target Zone: $0.56 – $0.68 Potential Upside: 72% ROI Time to Expiration: 199 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 24 at 4:57 PM
$KZR NEED TO SHUFFLE 14.7 MILLION SHARES ON U OFF THE BOOKS
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 22 at 9:28 PM
0 · Reply
Adrianople117
Adrianople117 Nov. 17 at 5:49 AM
$KZR Well there goes 500k shares... cant sell 500k at once otherwise it would collapse the stock. Wait for more fomr 13s to come out this week.
0 · Reply
d_risk
d_risk Nov. 12 at 10:28 PM
$KZR - Kezar Life Sciences, Inc. - 10Q - Updated Risk Factors KZR’s latest 10-Q risk factors expand on capital needs, clinical trial and regulatory hurdles, strategic alternatives, restructuring uncertainties, IP and patent challenges, executive retention, cybersecurity, global volatility, concentrated ownership, and new compliance and anti-takeover risks. #Biotechnology #Cybersecurity #CapitalNeeds #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/KZR/10-Q/2025-11-12
0 · Reply
Adrianople117
Adrianople117 Nov. 7 at 9:58 PM
$KZR possibly.... we will see with earnings how much cash they have now.
0 · Reply
Maddmike
Maddmike Nov. 7 at 9:06 PM
$KZR back to$5 🤔
0 · Reply
Adrianople117
Adrianople117 Nov. 4 at 6:28 PM
$KZR hmmm....
0 · Reply
Adrianople117
Adrianople117 Oct. 31 at 4:27 AM
$KZR hmmm.... first its ever dropped below 6... well have to see during market open what happens... curious
0 · Reply
brj1323
brj1323 Oct. 24 at 5:20 PM
$KZR adding some here
0 · Reply
Adrianople117
Adrianople117 Oct. 21 at 1:46 AM
$KZR alot of sell orders and price hasnt dropped. Usually means institutions selling. Stock is at 6.09 after hours. My opinion we will see 4 bucks in less than a couple weeks. Sure they had 90.1 m in sept but another clinical trial re do is expensive. And they burn 4m a month without the clinical trial costs.
0 · Reply
Raxothus
Raxothus Oct. 20 at 7:48 PM
EOD CONTINUATION FOLLOW-UP – 10/17/25 Tracking continuation watchlist from yesterday based on intraday highs vs. close ❌ $SPAI – Dropped from 9.00 to 7.38 (–18%), full fade after strong prior session. Failed continuation. ⚠️ $KZR – Moving sideways, no clear trend. Neutral. ✅ $DMRC – Closed 8.60, hit HOD 9.27 (+7.8%), solid continuation with controlled pullback. ✅ $SGHT – Closed 4.60, reached 5.14 (+11.7%), clean follow-through, strong intraday action. ✅ $VANI – Closed 1.70, now 1.83 (+7.6%), gradual continuation move. Recap: 5 total → 3 winners ($DMRC, $SGHT, $VANI), 1 fail ($SPAI), 1 neutral → 60% accuracy Leaders: $SGHT showed strongest continuation, $DMRC and $VANI held structure well; $SPAI was the only full fade. #vwap #smallcaps #daytrading #eodfollowup #continuation #snipersetup #accountability
0 · Reply
topstockalerts
topstockalerts Oct. 20 at 12:00 PM
$KZR where's it going once market opens?
0 · Reply
ChartChartist
ChartChartist Oct. 19 at 6:33 PM
$PCSA crypto play $KZR wow, missed that $AREB long hold is perfected $OMEX bullish $BCG massive Asset Mgmt company , 2.8m float , $2.20 bottom gonna rocket be in first !
0 · Reply
PaulLaurent
PaulLaurent Oct. 19 at 5:06 PM
🌅 4:00am EST Watchlist $SLS – New SEC report with corporate updates and cap-structure housekeeping. Focus on GPS (WT1) across prioritized indications. Watch next clinical milestones, partnering color, and cash runway disclosures that could frame Q4 catalysts. $VIVK – Multiple SEC updates following the $40M commodity intermediation term sheet. Track conversion to definitive docs, initial draws/use of proceeds, revenue ramp cadence, and any Nasdaq compliance implications. $KZR – Potential multi-day runner. Monitor premarket volume, VWAP reclaims, and prior HOD retests. $RANI – Potential multi-day runner. Look for higher-low structure, liquidity expansion, and tight risk on fades. $SLNH – Potential multi-day runner. Favor clean pullbacks to VWAP and momentum continuation. Tone: Filings and financing paths set the narrative. Favor VWAP/pivot reclaims, trim into strength, keep risk tight.
0 · Reply
strongii
strongii Oct. 19 at 3:40 PM
0 · Reply
AnalyticaInvestor
AnalyticaInvestor Oct. 19 at 12:38 PM
$GWH $ARTV $KZR $NUAI $CREV While everyone is chasing $GOLD and $SILVER, $KCP.V is preparing to drill one of the most under-the-radar copper targets in South America. ▸ Surrounded by major copper mines ▸ Fully funded 15,000m program ▸ Deep porphyry targets untouched ▸ Led by Oyu Tolgoi co-discoverer Doug Kirwin This could be the next major re-rate story in copper. Read the full breakdown here 👇 https://analyticainvestor.beehiiv.com/p/while-the-market-chased-metals-one-junior-quietly-positioned-for-a-breakout
0 · Reply